Kofituss Sedativo Tossetosse (Levodropropizine)

Levodropropizine works by inhibiting sensory nerve endings in the airways that trigger the cough reflex. By blocking these peripheral receptors, the drug reduces the afferent signals that lead to coughing, offering effective cough suppression while avoiding central nervous system activity.

The appropriate dose of Kofituss Sedativo Tossetosse is determined by a qualified healthcare professional based on the patient’s age, weight, and clinical condition. Prescribers set the exact regimen, and patients should follow the instructions provided on the prescription label.

Safety data for levodropropizine during pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should evaluate each case individually before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details and any required import documentation.

Unlike central agents such as codeine, levodropropizine acts peripherally and does not cause sedation or respiratory depression. This makes it a preferable option for patients who need cough relief without the risk of opioid‑related side effects, especially in populations where central depressants are contraindicated.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not refrigerate or freeze the medication, and ensure the container is tightly closed when not in use.

The medication is taken orally. Patients should swallow the tablet or liquid formulation whole with water, following the dosage instructions provided by their healthcare professional. It is not intended for sublingual or rectal administration.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, skin conditions like Stevens‑Johnson syndrome, and signs of liver injury. Patients should seek immediate medical attention if they experience rash, swelling, difficulty breathing, or jaundice.

Individuals with known hypersensitivity to levodropropizine or any excipients in the formulation should avoid the product. It is also contraindicated in patients with severe hepatic impairment until safety is established, and should be used with caution in pregnant or nursing women only when clearly indicated.